Webinar | March 23, 2021

A Quality By Design Approach To Viral Clearance: Predicting LRV Through The Use Of A Non-Infectious MVM Surrogate

To determine viral clearance efficacy of biomanufacturing steps, viruses are “spiked” into in-process solutions, processed and analyzed for reduction.  Due to the infectivity of these viruses, studies are conducted in BSL-2 facilities.  Costs and logistics limit analysis during process development.  Discussed here are results from several studies that utilized a non-infectious Mock Virus Particle (MVP) as an MVM surrogate.  The results demonstrated the value to be gained from such a QbD approach during process optimization.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online